Status:
COMPLETED
Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)
Lead Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Conditions:
Virus Diseases
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Maraviroc (MVC) is a drug, very well tolerated, it has been seen that MVC has properties of modulating the immune system, exerting an anti-inflammatory effect in different diseases. In COVID-19, very ...
Detailed Description
In this clinical trial the investigators want to evaluate if standard treatment together with Maraviroc (MVC) compared to standard treatment alone, achieves better clinical evolution in participants h...
Eligibility Criteria
Inclusion
- Subjects aged ≥ 18 years.
- Infection confirmed by SARS-CoV-2 by polymerase chain reaction (PCR) at least 3 days before randomization.
- Hospitalized or emergency patient in hospitalization phase.
- Mild / moderate pneumonia, with fever, persistent cough and severe asthenia, confirmed by imaging tests (conventional radiology or computerized axial tomography (CT)) with ambient air oxygen saturation (SatO2)\> 94%.
- Less than 12 days from the onset of symptoms.
- Women of childbearing potential must have a negative serum or urine pregnancy test prior to inclusion in the study and must commit to using highly effective contraceptive methods (intrauterine device, bilateral tubal occlusion, vasectomized partner, and sexual abstinence).
- Accepts written consent or oral informed in the case that due to the relevant security protocols, written consent is not possible.
Exclusion
- Patient with severe pneumonia confirmed by imaging test (conventional radiology or computerized axial tomography (CT)) with ambient air oxygen saturation (SatO2) ≤94%.
- Another acute active infection other than that produced by SARS-CoV-2.
- Chronic renal failure (estimated glomerular filtration ≤ 30 ml / min / 1.73 m2 or receiving renal replacement therapy in any of its modalities).
- Known HIV infection. Unless the patient has\> 500 CD4 + / mm3 and an undetectable viral load for more than 6 months.
- Active co-infection with known hepatitis B or C viruses.
- Cirrhosis, portal hypertension and / or hypersplenism of any etiology.
- Past or current neoplasms subsidiary to treatment with steroids, immunomodulators or chemotherapy
- Laboratory abnormalities.
- Concomitant use of drugs with major pharmacological interactions with the study drugs, according to the respective technical specifications of the products.
- Pregnancy.
Key Trial Info
Start Date :
February 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 8 2021
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT04710199
Start Date
February 23 2021
End Date
July 8 2021
Last Update
May 6 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario Virgen del Rocio
Seville, Spain, 41013
2
Hospital Universitario Virgen del Rocío
Seville, Spain, 41013